Bonus Biogroup

Bonus Biogroup Ltd. is an Israeli clinical-stage biotechnology company focused on regenerative medicine. It develops tissue engineering and cell therapy products intended to address unmet medical needs related to tissue damage, inflammation, and immune response. The company's two leading investigational product candidates are BonoFill, a personalized viable bone graft produced by tissue engineering from the patient's own cells for use in oral and maxillofacial surgery and orthopedic surgery, and MesenCure, a cell therapy for cytokine storm and life-threatening respiratory distress, manufactured from mesenchymal cells derived from the adipose tissue of healthy donors. Both products are in clinical trials. The company states that it aims to pioneer the future of regenerative medicine, with technologies designed to help millions live better and longer lives. Its research leverages the natural properties of mesenchymal cells to provide multi-functional therapeutic mechanisms that modulate inflammation and promote tissue repair. Bonus Biogroup is traded on the Tel Aviv Stock Exchange under the ticker BONS. It is led by founder and CEO Dr. Shai Meretzki, a biotech industry executive who previously founded Pluristem Therapeutics (now Pluri Inc.), and Executive Chairman Yosef Rauch, a finance and capital markets expert. In 2022 the company established its headquarters at the new Bonus Biogroup House in Haifa, Israel, a site designed to comply with GMP standards and dedicated to research, development, and clinical manufacturing. Bonus Biogroup's mission is to develop safe, effective, and affordable tissue engineering and cell therapy products to address severe conditions representing large markets with limited treatment options. The company operates through subsidiaries, including a wholly owned subsidiary, Bonus Therapeutic Ltd., and another subsidiary, Bonus Cellora Ltd., in which it holds 95.5% ownership. Its scientific advisory committee includes Prof. Nimrod Rozen, Prof. Yehuda Ullmann, and Dr. Ephraim Tzur.

Bonus Biogroup Ltd. was founded in October 1981 and has been listed on the Tel Aviv Stock Exchange since August 1993. The company is located in the MATAM Park in Haifa, Israel. Its chairman is Yosef Rauch and its CEO is Dr. Shai Meretzki. The scientific advisory committee includes Prof. Nimrod Rozen, Prof. Yehuda Ullmann, and Dr. Ephraim Tzur. The company has a wholly owned subsidiary, Bonus Therapeutic Ltd., and another subsidiary, Bonus Cellora Ltd., in which it holds 95.5% ownership. Bonus Biogroup is a clinical-stage biotechnology company developing next-generation therapies for a variety of indications in the regenerative medicine field. It leverages its knowledge and expertise to establish a technological platform that underpins the development of its leading product candidates, BonoFill and MesenCure. BonoFill is a personalized bone graft produced by tissue engineering from the patient's cells, for reconstruction of bone defects in oral and maxillofacial surgery and orthopedic surgery. The graft is tailored to the biological, physical, and clinical needs of the patient. The basis for the production of the living bone graft is mesenchymal cells derived from the patient's adipose tissue. The product is in clinical trials; the company estimated that marketing approval would be granted in 2024–2025. MesenCure is a drug for the treatment of cytokine storm that creates life-threatening respiratory distress. The drug is manufactured from mesenchymal cells derived from the adipose tissue of healthy donors and is intended for the treatment of inflammation in the respiratory system, whether caused by the novel coronavirus or any other virus, or by bacteria or exposure to other pathogens. The drug is in clinical trials in hospitals in Israel. In July 2021, the company reported significant success of the drug in treating severe COVID-19 patients. In 2022, the company established its headquarters at the new Bonus Biogroup House in Haifa, Israel. This site is designed to comply with GMP standards and is dedicated to the research, development, and clinical manufacturing of the company's products. The company is led by CEO Dr. Shai Meretzki, a biotech industry executive who founded multiple biotech companies, and Executive Chairman Yosef Rauch, a finance and capital markets expert, formerly the Chief Economist and Manager of the Economics Department at Leumi PIA. The leadership team brings expertise in biotechnology, regenerative medicine, cell therapy, regulatory affairs, and clinical development, supporting the advancement of the investigational therapies BonoFill and MesenCure through clinical trials and regulatory pathways.

• 2022

  Established headquarters at the new Bonus Biogroup House in Haifa, Israel.

• 2021

  In July, the company reported significant success of MesenCure in treating severe COVID-19 patients.

• 2008

  Dr. Shai Meretzki founded Bonus Biogroup and has served as CEO since its founding.

• 1993

  Initial public offering on the Tel Aviv Stock Exchange in August.

• 1981

  Company founded in October.

Clinical-stage biotechnology company developing next-generation regenerative medicine therapies.

• BonoFill

  A personalized viable bone graft produced by tissue engineering from the patient's own cells, for reconstruction of bone defects in oral and maxillofacial surgery and orthopedic surgery. The graft is tailored to the biological, physical, and clinical needs of the patient. The basis for the production of the living bone graft is mesenchymal cells derived from the patient's adipose tissue. The product is in clinical trials.

• MesenCure

  A drug for the treatment of cytokine storm that creates life-threatening respiratory distress. The drug is manufactured from mesenchymal cells derived from the adipose tissue of healthy donors and is intended for the treatment of inflammation in the respiratory system, whether caused by the novel coronavirus or any other virus, or by bacteria or exposure to other pathogens. The drug is in clinical trials in hospitals in Israel.

1. 1Homebonus-bio.com
2. 2About usbonus-bio.com
3. 3Companybonus-bio.com
4. 4Leadershipbonus-bio.com
5. 5בונוס ביוגרופhe.wikipedia.org
6. 6Bonus Biogroup Ltd.wikidata.org